Project Grant R41AA032157
- This federal Project Grant award of $551,464 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273). The funding will support a 5-year research project led by the Palo Alto Veterans Institute For Research (Pavir) to assess the impact of deep transcranial magnetic stimulation (DTMS) on neural targets associated with alcohol use disorder. The key objectives of the research project are to: 1) evaluate the efficacy of active...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $498,002 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Illinois to conduct a study aimed at increasing alcohol abstinence in young adults with alcohol use disorder (AUD). The overall goals of this 3-year project are to: (1) test the efficacy of combining contingency management (CM) with problem-solving therapy (CM-PST) versus CM alone in a 2-arm pilot randomized controlled trial, and...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $390,454 Project Grant to Envisbio LLC to develop novel therapeutic aptamers targeting phosphodiesterase 4B (PDE4B) for the treatment of alcohol use disorder (AUD). The project aims to identify and characterize PDE4B-specific aptamers that can modulate PDE4B activity, with the goal of advancing these modulators into in vivo testing and eventual human clinical trials for...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $901,666 Project Grant to Research Triangle Institute (RTI International) to develop small molecule modulators of the RXFP3 receptor as potential therapeutic agents for alcohol use disorder (AUD). The project aims to further optimize and evaluate the effectiveness of the RXFP3 negative allosteric modulators (NAMs) RLX-33 and RLX-79 in animal models of alcohol...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), awarded a $999,393 Cooperative Agreement to Stress Therapeutics, Inc., a California-based pharmaceutical company, to conduct Investigational New Drug (IND)-enabling studies for a novel therapeutic to treat Alcohol Use Disorder (AUD). The key products and services to be delivered include: 1) Manufacture and validation of the test article for IND-enabling studies; 2) Development and...
- Under a $368,673 Project Grant from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded on September 25, 2023, Artiam Bio Inc., a minority-owned small disadvantaged biotechnology company, is developing and evaluating second-generation partial inverse agonists targeting the type 1 cannabinoid (CB1) receptor as a potential therapy for alcohol use disorder (AUD). Artiam Bio is conducting preclinical efficacy studies of its lead CB1 receptor partial inverse agonist compound in rat...
- This $673,500 Project Grant from the National Institutes of Health's National Institute on Alcohol Abuse and Alcoholism will fund Amygdala Neurosciences, Inc. to develop new, potent, selective, and reversible inhibitors of aldehyde dehydrogenase 2 (ALDH2) for the treatment of alcohol use disorder. The goal is to implement an innovative screening technology to discover novel compounds that reduce craving and alcohol consumption by selectively inhibiting ALDH2 in a reversible manner, avoiding...
- This federal Project Grant award of $423,313, provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273), aims to develop an AI-driven platform for identifying potential therapeutic candidates for Alcohol Use Disorder (AUD). The award to Biosymetrics Inc., based in Huntington, NY, will leverage the company's existing AI-based zebrafish behavioral screening technology and AUD-specific experimental findings to create a commercial...
- This federal Project Grant award of $539,237 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), supports research on a novel deep brain stimulation (DBS) approach that combines spike-timing dependent plasticity (STDP) to selectively modulate maladaptive neural plasticity associated with alcohol addiction and other neurological/psychiatric disorders. The project aims to apply precisely-timed STDP-DBS stimulation in two brain...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $399,076 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Tennessee Health Science Center in Memphis, TN. The purpose of this grant is to develop a rapid and reliable platform for evaluating and repurposing FDA-approved drugs to target chronic alcohol tolerance and dependence associated with Alcohol Use Disorder (AUD). The project will leverage the nematode Caenorhabditis elegans as an...
The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $305,545 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Spark Biomedical Inc. to study the use of transcutaneous auricular neurostimulation (TAN) as a treatment for alcohol use disorder. The research aims to investigate the efficacy of TAN in reducing alcohol withdrawal symptoms and developing neuroimaging biomarkers for alcohol use disorder. Spark Biomedical, a small disadvantaged business specializing in neuromodulation technologies, will conduct this 1-year project from September 2025 to August 2026. The research initiative seeks to provide a comprehensive clinical package that advances the application of TAN as a non-pharmacological intervention for alcohol use disorder.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $305.5k | 8/26/25 |